Howell R W, Narra V R, Rao D V
Department of Radiology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark 07103.
J Nucl Med. 1992 Feb;33(2):277-81.
One of the most promising areas for cancer therapy with administered radiopharmaceuticals is the treatment of very small tumors and micrometastases. Small tumors and micrometastases, however, may be rapidly growing at the time of treatment, resulting in a substantial change in mass during the period of irradiation. In this work, the formalism required to calculate the average absorbed dose to rapidly growing tumors is developed and applied to an in vitro tumor model. Further application to in vivo human myeloma tumors reveals that tumor growth may have a significant effect on the average dose delivered to the tumor from incorporated radionuclides. These considerations may assist in establishing dose-response relationships necessary for radiopharmaceutical cancer therapy.
使用放射性药物进行癌症治疗最有前景的领域之一是治疗非常小的肿瘤和微转移灶。然而，小肿瘤和微转移灶在治疗时可能生长迅速，导致在照射期间质量发生显著变化。在这项工作中，开发了计算快速生长肿瘤平均吸收剂量所需的形式体系，并将其应用于体外肿瘤模型。对体内人类骨髓瘤肿瘤的进一步应用表明，肿瘤生长可能对从掺入的放射性核素传递到肿瘤的平均剂量有显著影响。这些考虑因素可能有助于建立放射性药物癌症治疗所需的剂量反应关系。
